Motoneuron Disease: Clinical

Abstract

ALS is a neurodegenerative disease in which the primary symptoms result in progressive neuromuscular weakness. Recent studies have highlighted that there is significant heterogeneity with regard to anatomical and temporal disease progression. Importantly, more recent advances in genetics have revealed new causative genes to the disease. New efforts have focused on the development of biomarkers that could aid in diagnosis, prognosis, and serve as pharmacodynamics markers. Although traditional pharmaceuticals continue to undergo trials for ALS, new therapeutic strategies including stem cell transplantation studies, gene therapies, and antisense therapies targeting some of the familial forms of ALS are gaining momentum.

Trial registration: ClinicalTrials.gov NCT02290886.

Keywords: Diagnosis; Exercise; Frontotemporal dementia; Gene therapy; Heterogeneity; Nutrition; Phenotype; Respiratory management; Stem cell therapy.